Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Next-generation CAR gene-modified cell therapy: overcoming resistance and exploring novel applications.

View Full Paper
Ask AI
Bookmark
Share

Authors

RSReona Sakemura

Discussion

Loading...

Member takes

Overview

This research demonstrates enhanced efficacy of dual-specific CAR T-cells against cancer-associated fibroblasts and improving GvHD treatment.

Key Points

  • Dual-specific CAR T-cells targeting cancer-associated fibroblasts enhanced efficacy against multiple myeloma.
  • Research showed that CAFs promote CAR T-cell exhaustion through pathways involving TGF-β and IL-10.
  • Development of Ecad CAR-MSCs reduced graft-versus-host disease (GvHD) via selective accumulation in intestinal epithelium.
  • These findings suggest promising clinical applications for improving outcomes in cellular therapy.

Cite This Study

Reona Sakemura (2025) studied this question.

synapsesocial.com/papers/68c24236b210217d647a2622https://doi.org/10.11406/rinketsu.66.679
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  2. 2Development of a novel CD19/BCMA dual CAR-T for autoimmune diseases2025 · 1 citations
  3. 3Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies2025 · 1 citations
  4. 4Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma2025
  5. 5BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations